Femasys announces publication of ‘positive’ results from FemBloc trials

Femasys (FEMY) announces the peer-reviewed publication of “positive data” from its initial clinical trials of FemBloc permanent birth control in the Journal of Gynecology & Reproductive Medicine. “The pregnancy rate for FemBloc subjects, who met trial eligibility and were determined bilaterally occluded after a confirmation test three months post-FemBloc was 0%. This is significantly lower than the performance goal of 6% based on the historical control, surgical sterilization. Safety reports were consistent with those typically observed for intrauterine transcervical procedures, with no on-going safety concerns through five years. There were no reports of serious adverse events. The vast majority of subjects stated they would probably or definitely recommend FemBloc, and investigator satisfaction was similarly high,” the company stated. “This peer-reviewed publication detailing positive prospective, multi-center clinical trial data for FemBloc brings Femasys closer to achieving our goal of providing a safer, more accessible in-office alternative to longstanding surgical sterilization for permanent contraception, without compromising effectiveness,” stated Kathy Lee-Sepsick, CEO of Femasys. “The investigators who participated in these clinical trials share a commitment to advancing women’s health by expanding contraceptive options with FemBloc, a much-needed advancement in permanent birth control.”